
ITEM 1: BREAKING DOWN MARGINS - Q2 MARGIN WALK TO NORMALIZED MARGINS









Spectrum Therapeutics

ITEM 2: BREAKING DOWN ADJUSTED EBITDA





ITEM 3: INVENTORY, SUPPLY & DEMAND - FURTHER DETAILS



- As of 9/30/19, Canopy held \$461.8M of inventory and \$110.3M of biological assets, for a total of \$572.1M.
- Included is **\$219M** of fair value adjustments, which are adjusted quarterly based on net realizable value calculations.
- All other inventory & biological assets of \$65M pertain to international locations, including US Hemp farming costs, C3 inventory, S&B inventory, etc.
- Canada inventory and biological assets at cost is \$288M, and includes raw materials, consumables, semi-finished goods such as resin and isolate, WIP and finished goods across all product formats.






Spectrum

ITEM 3: INVENTORY, SUPPLY & DEMAND - FURTHER DETAILS

Flower Supply & Demand Modeling



- The Company continually models projected demand versus production capacity across many scenarios, largely driven by number of store openings.
- This models an incremental 40 new stores monthly in Ontario starting in January 2020*, along with a range of assumptions.
- In this scenario, current production and demand equalize in June 2020, with 4.5 months of accumulated inventory.
- * Alberta added approx. 40 stores per month for the 5 months ended Sep 2019.





4